• Home
  • Deal Card – Emmes

The Transaction

Delancey Street Partners is pleased to announce the following transaction:

March 2019
The Emmes Corporation
Majority recapitalization with Behrman Capital
Sector: Healthcare

Delancey Street Partners served as the exclusive financial advisor to The Emmes Corporation

Delancey Street Partners is pleased to announce that we served as exclusive financial advisor to The Emmes Corporation (“Emmes” or the “Company”) on its majority recapitalization with Behrman Capital (“Behrman”). Over several years we assisted the Company in preparing for a transaction. This process began with assessing shareholder objectives and included evaluating strategic alternatives, recommending initiatives to enhance value and preparing for the transaction process. Delancey then executed a tailored process that identified Behrman as the best partner to support Emmes in its next phase of growth. We are honored to have been part of the Emmes story and look forward to the Company’s continued success.

Emmes is a leading contract research organization that partners with public, private foundation, and commercial biopharmaceutical clients to develop new treatment options for diseases and disorders impacting public health. The Company provides a full suite of clinical research services as well as a number of supporting specialty, analytical, and technology services. In particular, Emmes is the pre-eminent provider of biostatistics-related services such as protocol development, study design, study monitoring, data analysis, data management, and data reporting with expertise across a wide range of therapeutic areas. Emmes has more than 600 highly skilled and experienced employees across the U.S., Canada, and India, and serves clients globally. The Emmes Corporation was founded in 1977 and is headquartered in Rockville, Maryland.

Based in New York City and San Francisco, Behrman Capital was founded in 1991 by Grant G. and Darryl G. Behrman. The firm invests in management buyouts, leveraged buildups and recapitalizations of established growth businesses. The company’s investments are focused in three industries: aerospace and defense, healthcare services, and specialty manufacturing and distribution. The firm has raised in excess of $3.0 billion since inception and is currently investing out of its sixth fund.

Delancey Street Partners is an independent, industry-focused investment bank. We serve CEOs, Entrepreneurs, Shareholders and Boards of Directors of high growth and middle market private and public companies. Our services include strategic advisory, capital raising and independent board advice. We advise on sell-side and buy-side M&A, growth capital financings and recapitalizations. Our focus sectors include Healthcare, Business & Technology Services, Industrial & Industrial Technology, and Infrastructure. We form long-term partnerships with our clients and commit to managing each engagement with senior professionals who bring years of experience and insight.
The transaction was completed March 1, 2019.

The principals of Delancey Street Partners have significant experience serving the Healthcare industry. To learn about our experience in Healthcare, please click here.

For additional information about this transaction, please contact:

B. Andrew Schmucker
Managing Partner

William J. Filip
Managing Director

Delancey Street Partners

Our offices are located in the suburbs of Philadelphia:
Five Tower Bridge, Suite 420 | 300 Barr Harbor Drive | West Conshohocken, PA 19428
(484) 533-6300

© 2017 Delancey Street Partners, LLC | Disclosures

Securities offered through DSP Securities, LLC. Member SIPC | Member FINRA, all other transactions effectuated through Delancey Street Partners, LLC

Check the background of this investment professional on FINRA’s BrokerCheck »